Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, and Singapore. The company operates through two segments, Testing Services, and Research and Development. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; testing and data analysis services for personal and research testing; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases, as well as Databank for health and biome data. The company was incorporated in 2017 and is based in Brisbane, Australia.
| Market Capitalization | $120.4478 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.113 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.05 |
| EBITDA | -18,588.292 |
| Profit Margin | -2.3395 |
| Operating Margin TTM | -3.7324 |
| Return on Assets TTM | -0.2926 |
| Return on Equity TTM | -0.3517 |
| Revenue TTM | 5,420.136 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2018-12-31 | 1,828.16 | 1,012.86 | 815.3 | |
| 2019-12-31 | 2,909.03 | 1,482.4 | 1,426.63 | |
| 2020-12-31 | 3,732.44 | 1,668.4 | 2,064.04 | |
| 2021-12-31 | 4,688.645 | 2,322.93 | 2,365.715 | 18,637.779 |
| 2022-12-31 | 5,420.14 | 2,741.87 | 2,678.27 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2018-12-31 | 10,995.3 | 13,990.52 | 1,434.41 | 0 | 277.22 | 17,887.99 |
| 2019-12-31 | 6,847.54 | 10,807.82 | 3,103.92 | 0 | 135.89 | 19,289.29 |
| 2020-12-31 | 12,978.6 | 18,487.71 | 3,551.61 | 0 | 0 | 33,482.96 |
| 2021-12-31 | 30,580.673 | 39,479.217 | 5,943.013 | 841.364 | 62,884.01 | |
| 2022-12-31 | 18,681.59 | 46,953.03 | 8,379.2 | 0 | 80,373.99 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2018-12-31 | -3,620.56 | 9,262.6 | ||||
| 2019-12-31 | -4,323.28 | -4,098 | ||||
| 2020-12-31 | -7,181.58 | 6,081.3 | 12,978.604 | |||
| 2021-12-31 | -11,470.429 | -10,448.81 | 17,602.069 | 12,978.604 | 30,580.673 | 425.349 |
| 2022-12-31 | -12,680.212 | -12,393.83 | 1,463.2 | 30,580.673 | 32,043.874 |